RCUS

RCUS

USD

Arcus Biosciences Inc. Common Stock

$19.830+0.130 (0.660%)

实时价格

Healthcare
生物技术
美国

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$19.700

最高价

$20.500

最低价

$19.691

成交量

0.41M

公司基本面

市值

2.4B

所属行业

生物技术

国家/地区

United States

交易统计

平均成交量

1.18M

交易所

NYQ

货币

USD

52周价格范围

最低价 $6.5当前价 $19.830最高价 $22.11

相关新闻

BusinessWire

Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune

查看更多
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
Analyst Upgrades

Goldman Sachs Maintains Neutral on Arcus Biosciences, Raises Price Target to $16

Goldman Sachs analyst Salveen Richter maintains Arcus Biosciences with a Neutral and raises the price target from $14 to $16.

查看更多
Goldman Sachs Maintains Neutral on Arcus Biosciences, Raises Price Target to $16
Analyst Upgrades

Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $56

Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences with a Buy and raises the price target from $54 to $56.

查看更多
Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $56
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Arcus Biosciences, Raises Price Target to $28

HC Wainwright & Co. analyst Emily Bodnar maintains Arcus Biosciences with a Buy and raises the price target from $24 to $28.

查看更多
HC Wainwright & Co. Maintains Buy on Arcus Biosciences, Raises Price Target to $28
BusinessWire

Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update

Casdatifan, a potential best-in-class HIF-2a inhibitor, demonstrated 12.2 months median progression-free survival (mPFS) and 18-month landmark PFS of 43% in a pooled analysis of 121 patients with late-line kidney

查看更多
Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update
Analyst Upgrades

Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $54

Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences with a Buy and raises the price target from $47 to $54.

BusinessWire

Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study

First overall survival (OS) results from Arm A1 of the Phase 2 EDGE-Gastric study will be presented on October 18 at the European Society for Medical Oncology (ESMO) 2025 Congress These data support the ongoing